Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT ID: NCT00041015

Last Updated: 2014-01-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2001-09-30
• Study Completion Date: 2002-11-30

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating extensive-stage small cell lung cancer.

PURPOSE: Randomized phase III trial to compare different chemotherapy regimens in treating patients who have extensive-stage small cell lung cancer.

Detailed Description

OBJECTIVES:

• Compare the overall survival of patients with chemotherapy-naive extensive stage small cell lung cancer treated with cisplatin and oral topotecan vs cisplatin and etoposide.
• Compare the response rates, response duration, and time to progression in patients treated with these regimens.
• Compare the tolerability of these regimens in these patients.
• Compare the patient-perceived disease status and well being in patients treated with these regimens.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to gender, ECOG performance status (0 vs 1 vs 2), lactate dehydrogenase (less than 1.5 times upper limit of normal (ULN) vs 1.5 times ULN or greater), and country. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral topotecan once daily on days 1-5 and cisplatin IV on day 5.
• Arm II: Patients receive cisplatin IV on day 1 and etoposide IV over at least 30 minutes on days 1-3.

Treatment in both arms repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, prior to each course, at 4 weeks after study, and then every 4 weeks for 16 weeks.

Patients are followed at 4 weeks, every 4 weeks for 16 weeks, and then every 3 months thereafter.

PROJECTED ACCRUAL: Approximately 760 patients (380 per treatment arm) will be accrued for this study within 18 months.

Conditions

Lung Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

oral topotecan plus cisplatin IV

oral topotecan once daily on days 1-5 and cisplatin IV on day 5

Group Type: ACTIVE_COMPARATOR

cisplatin

Intervention Type: DRUG

topotecan hydrochloride

Intervention Type: DRUG

Cisplatin IV plus etoposide IV

Cisplatin IV on day 1 and etoposide IV over at least 30 minutes

Group Type: EXPERIMENTAL

cisplatin

Intervention Type: DRUG

etoposide

Intervention Type: DRUG

Interventions

cisplatin

Intervention Type: DRUG

etoposide

Intervention Type: DRUG

topotecan hydrochloride

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed extensive stage small cell lung carcinoma (SCLC)
• No prior chemotherapy for SCLC OR
• No chemotherapy within 5 years of diagnosis of SCLC
• Prior radiotherapy to measurable or nonmeasurable disease field allowed provided radiotherapy was completed at least 6 weeks ago and the disease is demonstrated to be progressing
• No clinical signs or symptoms of brain and/or leptomeningeal metastases by CT scan or MRI

• Brain and/or leptomeningeal metastases that are asymptomatic on neurologic exam are allowed provided metastases do not require corticosteroid therapy to control symptoms

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• At least 3 months

Hematopoietic:

• Hemoglobin at least 9.0 g/dL
• WBC at least 3,500/mm3
• Platelet count at least 100,000/mm3
• Neutrophil count at least 1,500/mm3

Hepatic:

• Bilirubin no greater than 2.0 mg/dL
• SGOT and SGPT no greater than 2 times the upper limit of normal (ULN) (5 times ULN if liver metastases present)
• Alkaline phosphatase no greater than 2 times ULN (5 times ULN if liver metastases present)

Renal:

• Creatinine no greater than 1.5 mg/dL
• Creatinine clearance at least 60 mL/min
• No pre-existing renal impairment that would preclude cisplatin use

Gastrointestinal:

• No clinical evidence of any gastrointestinal (GI) conditions including:

• Removal of a portion of the stomach
• History of recent obstruction of the GI tract
• GI autonomic neuropathy
• Ulcerative colitis
• Crohn's disease
• Malabsorption syndrome
• Treatment with cyclosporine that would alter absorption or GI motility
• No other conditions that would preclude absorption of oral topotecan

Other:

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception for 3 months prior to study, during, and for at least 1 month after study
• No active infection
• No other prior or concurrent malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or localized low-grade prostate cancer
• No other concurrent severe medical problems that would expose the patient to extreme risk or preclude study compliance
• No prior allergic reactions to compounds chemically related to study drugs
• No pre-existing hearing impairment that would preclude cisplatin use
• No overall medical condition for which study drugs would be inappropriate

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No concurrent immunotherapy for SCLC

Chemotherapy:

• See Disease Characteristics
• No other concurrent chemotherapy for SCLC

Endocrine therapy:

• See Disease Characteristics
• No concurrent hormonal therapy for SCLC

Radiotherapy:

• See Disease Characteristics
• At least 24 hours since prior radiotherapy with no expected bone marrow suppression
• Recovered from prior palliative radiotherapy (e.g, nausea and vomiting from radiation of the epigastrium)
• No concurrent radiotherapy for SCLC
• No concurrent radiotherapy for palliation of bone metastases or CNS lesions unless approved by the investigator

Surgery:

• At least 3 weeks since prior major surgery (a shorter period is allowed if deemed in the best interest of the patient)

Other:

• More than 30 days or 5 half-lives (whichever is longer) since prior investigational drugs
• No other concurrent investigational therapy for SCLC
• No concurrent cyclosporine
• No concurrent drugs that would preclude absorption of oral topotecan

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Case Comprehensive Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Nathan Levitan, MD

Role: STUDY_CHAIR

Case Comprehensive Cancer Center

Locations

Ireland Cancer Center

Cleveland, Ohio, United States

Countries

United States

Other Identifiers

CWRU-070144

Identifier Type: -

Identifier Source: secondary_id

SB-389

Identifier Type: -

Identifier Source: secondary_id

SB-SKF-104864A

Identifier Type: -

Identifier Source: secondary_id

SB-SKF-1501

Identifier Type: -

Identifier Source: secondary_id

NCI-G02-2092

Identifier Type: -

Identifier Source: secondary_id

SKF1501

Identifier Type: -

Identifier Source: org_study_id